Cinclus Pharma Ag
🇸🇪Sweden
- Country
- 🇸🇪Sweden
- Ownership
- Private
- Established
- 2014-01-01
- Employees
- 11
- Market Cap
- -
- Website
- http://www.cincluspharma.com
Relative Bioavailability of Linaprazan for the Test Formulation vs. Reference Formulation
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2022-11-25
- Last Posted Date
- 2023-01-18
- Lead Sponsor
- Cinclus Pharma AG
- Target Recruit Count
- 54
- Registration Number
- NCT05627518
- Locations
- 🇸🇮
CRS d.o.o., Ljubljana, Ukmarjeva Ulica 6, Slovenia
A Study to Investigate the Pharmacokinetics and ECG Effects of Linaprazan Glurate
Phase 1
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2022-07-22
- Last Posted Date
- 2024-02-07
- Lead Sponsor
- Cinclus Pharma AG
- Target Recruit Count
- 113
- Registration Number
- NCT05469854
- Locations
- 🇸🇪
CTC Clinical Trial Consultants AB, Uppsala, Sweden
A Study in Patients With Erosive Esophagitis to Investigate Safety, Tolerability, and Healing Rates After 4 Weeks Treatment of X842 or Lansoprazole and Symptom Pattern During Subsequent 4 Weeks Treatment With Lansoprazole
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2021-09-24
- Last Posted Date
- 2023-11-01
- Lead Sponsor
- Cinclus Pharma AG
- Target Recruit Count
- 248
- Registration Number
- NCT05055128
- Locations
- 🇧🇬
DCC XIV Sofia, Sofia, Sofia-Grad, Bulgaria
🇧🇬Medical Centre Asklepii, Dupnitsa, Bulgaria
🇧🇬Medical Center Prolet EOOD, Ruse, Bulgaria
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of X842 in Human: A Single/Multiple Ascending Dose Study
Early Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2017-04-07
- Last Posted Date
- 2017-11-07
- Lead Sponsor
- Cinclus Pharma AG
- Target Recruit Count
- 39
- Registration Number
- NCT03105375
- Locations
- 🇸🇪
Clinical Trial Consultants, Uppsala, Sweden
© Copyright 2024. All Rights Reserved by MedPath